14 completed, 1 terminated, 1 unknown. 16 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 14, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Glucagon-Like Peptide 1: new trials by email Literature Review of Glucagon-Like Peptide 1 trials Research Report on Glucagon-Like Peptide 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People. NNC9204-1513, Glucagon, Placebo - Diabetes, Diabetes Mellitus, Type 1 | Phase 1 | Completed | Novo Nordisk A/S | 36 | 2018-02-05 | 2018-09-05 |
| A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus Nasal Glucagon, Intramuscular Glucagon - Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 1 | Completed | Eli Lilly and Company | 70 | 2017-11-10 | 2019-09-23 |
| In Vivo Assessment of Cellular Metabolism in Humans Somatostatin, Glucagon - Normal Cellular Metabolism | Phase 1 | Completed | K. Sreekumaran Nair | 17 | 2016-07-01 | 2022-08-03 |
| Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia Glucagon (ZP-Glucagon), Glucagon (GlucaGen) - Hypoglycemia | Phase 1 | Completed | Zosano Pharma Corporation | 16 | 2015-01-01 | 2016-08-16 |
| The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure Glucagon-Like Peptide 1 - Heart Failure | Phase 1 | Completed | Papworth Hospital NHS Foundation Trust | 10 | 2014-06-01 | 2018-04-05 |
| Incretin Regulation of Insulin Secretion in Monogenic Diabetes GLP-1, Exendin 9-39 - Monogenic Diabetes | Phase 1 | Completed | University of Chicago | 10 | 2014-01-01 | 2017-04-10 |
| Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus GLP-1, SC, Standard Medical Treatment - Type 2 Diabetes | Phase 1 / Phase 2 | Unknown | Diabetes Care Center of Nanjing Military Command | 100 | 2013-10-01 | 2014-02-20 |
| Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery Roux-en-Y, GIP-infusion, GLP-1 - Type 2 Diabetes, Obesity | Phase 1 | Completed | Turku University Hospital | 36 | 2013-01-01 | 2021-10-20 |
| GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans GLP-1, Intravenous saline - Functional Gastrointestinal Disorders | Phase 1 | Completed | Uppsala University | 12 | 2012-09-01 | 2018-08-09 |
| Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates glucagon like peptide-1, glucose control - Type 2 Diabetes | Phase 1 / Phase 2 | Terminated | Albert Einstein College of Medicine | 20 | 2010-08-12 | 2024-02-28 |
| Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients ROSE-010, Placebo - Irritable Bowel Syndrome Constipation Predominant | Phase 1 / Phase 2 | Completed | Mayo Clinic | 52 | 2010-01-01 | 2013-05-31 |
| GLP 1 for Intraoperative Glycemic Control GLP 1, normal saline solution placebo - Hyperglycemia, Hypoglycemia | Phase 1 | Completed | University of Pennsylvania | 80 | 2008-12-01 | 2012-02-16 |
| Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers Glucagen, Mayne Glucagon - Hypoglycemia | Phase 1 | Completed | Hospira, now a wholly owned subsidiary of Pfizer | 28 | 2007-08-01 | 2017-03-20 |
| Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans GLP-1 control, GLP-1 and Exendin(9-39) 300, saline control - Hyperglycemia | Phase 1 | Completed | Ludwig-Maximilians - University of Munich | 6 | 2006-11-01 | 2011-10-04 |
| GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose Glucose-insulinotropic peptide, Glucagon-like peptide-1 - Physiology, Gastroenterology | Phase 1 | Completed | Uppsala University | 15 | 2006-08-01 | 2010-03-03 |
| A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002) MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg - Type 2 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2005-07-01 | 2015-08-19 |
Diabetes Mellitus, Type 2 (5) · Hypoglycemia (4) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 1 (2) · Hyperglycemia (2) · Insulin Resistance (2) · Irritable Bowel Syndrome (2) · Constipation (1) · Endocrine System Diseases (1) · Gastrointestinal Diseases (1) · Glucose Metabolism Disorders (1) · Heart Failure (1) · Ichthyosis Bullosa of Siemens (1) · Metabolic Diseases (1) · Obesity (1)
Uppsala University (2) · Albert Einstein College of Medicine (1) · Diabetes Care Center of Nanjing Military Command (1) · Eli Lilly and Company (1) · Hospira, now a wholly owned subsidiary of Pfizer (1) · K. Sreekumaran Nair (1) · Ludwig-Maximilians - University of Munich (1) · Mayo Clinic (1) · Merck Sharp & Dohme LLC (1) · Novo Nordisk A/S (1) · Papworth Hospital NHS Foundation Trust (1) · Turku University Hospital (1) · University of Chicago (1) · University of Pennsylvania (1) · Zosano Pharma Corporation (1)
United States (5) · Germany (3) · Sweden (2) · United Kingdom (2) · Australia (1) · China (1) · Finland (1)
Daniel T Stein, MD (1) · Joerg Schirra, MD (1) · K Sreekumaran Nair (1) · Michael Camilleri, MD (1) · Neale Cohen, MD (1) · Per M Hellstrom, MD, PhD (1) · Pirjo Nuutila, Prof (1) · Siri Atma W Greeley, MD, PhD (1) · Stuart Mair (1) · Xiangjin Xu, Professor (1)
PMID 18298441, PMID 22517769, PMID 27143183, PMID 28096259, PMID 29177486, PMID 30598343, PMID 32514794, PMID 35363252, PMID 38444629, PMID 8550855, PMID 9525985
2005 (1), 2016 (1), 2017 (1), R01DK061644 (1), U24DK100469 (1), UL1RR024150 (1)